Enveric Biosciences Elevates EB-003 To Lead Development Candidate, Provides Strategic Outlook And Pipeline Update
Enveric Biosciences Elevates EB-003 To Lead Development Candidate, Provides Strategic Outlook And Pipeline Update
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds
EB-003是一种新型的神经可塑性分子，旨在治疗严重的心理健康障碍，而不会产生通常与致幻剂基化合物相关的幻觉效应。
Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025
Enveric正在推进EB-003的临床前开发，预计在2025年初就进行IND会议。
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other neuroplastogens developed by Enveric are designed to promote neuroplasticity without inducing hallucinations, a hallmark side effect of many psychedelic and psychedelic-inspired compounds. Enveric is currently advancing pre-clinical development activities for EB-003 and targeting a Pre-IND meeting with the U.S. Food and Drug Administration (FDA) for early 2025.
Enveric Biosciences（纳斯达克：ENVB）（“Enveric”或“公司”），一家致力于开发新型神经可塑性小分子治疗抑郁症、焦虑症和成瘾性障碍的生物技术公司，今天宣布，该公司正在优先发展其首个心理健康障碍的新型疗法EB-003。Enveric开发的EB-003和其他神经可塑性物质旨在促进神经可塑性，而不会引起许多致幻剂和致幻剂类药物引起的幻觉等典型副作用。Enveric目前正在推进EB-003的临床前开发工作，并计划在2025年初与美国食品和药物管理局（FDA）进行IND会议。